Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

s.a. alcon-couvreur n.v - lodoxamide - lodoxamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sifi s.p.a. - lodoxamide - lodoxamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

alcon italia spa - lodoxamide - lodoxamide

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - loperamidi hydrochloridum - loperamid streuli 2 mg - loperamidi hydrochloridum 2 mg, lactosum monohydricum 225.5 mg, talco, kapselhülle: gelatina, pro capsula. - antidiarrhoikum - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva b.v. - lacosamide - lacosamide

Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a. - lacosamide - epilessia, parziale - antiepilettici, - lacosamide ucb è indicato come monoterapia e in terapia aggiuntiva nel trattamento di parziale-inizio convulsioni con o senza secondaria generalizzazione in adulti, adolescenti e bambini a partire dai 4 anni di età con epilessia.

Unione Europea - italiano - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilessia - antiepilettici, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - lacosamide - epilessia - antiepilettici, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - loperamidi hydrochloridum - compresse rivestite con film - loperamidi hydrochloridum 2 mg, cellulosum microcristallinum, lactosum monohydricum 42.8 mg, magnesii stearas, maydis amylum, copovidonum, silica colloidalis anhydrica, Überzug: hypromellosum, macrogolum 6000, dimeticonum, e 200, methylcellulosum, pro compresso obducto. - diarrea - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

desitin pharma gmbh - lacosamidum - compresse rivestite con film - lacosamidum 50.00 mg, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, hydroxypropylcellulosum, cellulosum microcristallinum silicificatum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, e 171, talcum, e 132, e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - antiepileptikum - synthetika